Summary of the American College for Advancement in Medicine May 2005 Conference: Menopause, Andropause: Power in Transition by Feig, Stephen A. et al.
eCAM 2005;2(3)413–419
doi:10.1093/ecam/neh113
Meeting Report
Summary of the American College for Advancement in
Medicine May 2005 Conference
Menopause, Andropause: Power in Transition
Stephen A. Feig
1, Eleanor Hynote
2, Neal Speight
3, Allan Magaziner
4, Ralph A. Miranda
5
and Michael B. Schachter
6
1Integrative Medical Consulting, 208 Vista Bella Drive, Santa Cruz, CA 95060,
2Phoenix Wellcare, 935 Trancas
Street Suite 1A, Napa, CA 94558,
3The Center For Wellness, 2317 Randolph Road, Charlotte, NC 28207,
4University
of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 1907 Greentree Road, Cherry Hill,
NJ 08003, and
5Wholistic Health Center, Laser Surgery Associates, The ECP Center, RR #12 Box 108, Greensburg,
PA 15601 and
6Schachter Center for Complementary Medicine, 2 Executive Boulevard, Suite 202, Suffern,
NY 10901, USA
The American College for Advancement in Medicine’s
(ACAM) 63rd International Educational Symposium on Com-
plementary, Alternative and Integrative Medicine (CAIM)
was held on May 18–22, 2005 at Disney’s Coronado Springs
Resort in Orlando, FL, USA. ACAM’s scientific symposium
brought together physicians and scientists from 13 countries
for a comprehensive educational program on the evaluation
and treatment of age-associated hormone deficiency with
special attention to the use of bioidentical hormones in andro-
pause and menopause.
ACAM’s Spring 2005 convocation, entitled ‘Menopause,
Andropause: Power in Transition’, addressed a multitude of
topics relevant for physicians and scientists interested in
improving their understanding of safe and effective hormone
replacement therapy, nutritional intervention and the lifestyle
modifications needed in order to ensure healthier and longer
lives as our population transitions into middle age. The scient-
ific presentations focused upon the use of bioidentical hor-
mone supplementation for the treatment of aging and a wide
variety of illnesses. Keynote presentations highlighted the
adverse consequences of endocrine disrupting chemicals on
human health along with recent advances in predictive genom-
ics testing for evaluating both risks and benefits of hormone
replacement therapy. Evidence-based protocols were presen-
ted for the use of bioidentical hormones in the treatment of
disorders of the endocrine, reproductive and cardiovascular
systems.
As a growing body of research has demonstrated a signific-
ant increase in disease risk in menopausal women taking
conventional non-bioidentical hormone replacement therapy
(1,2), the conference served as a testament to the over-
whelming professional interest in the use of bioidentical
hormones and CAIM therapies for treating disorders of hor-
monal senescence. Over 350 physicians and other health pro-
fessionals convened in Orlando at ACAM’s ‘Menopause,
Andropause: Power in Transition’ conference, in order to
learn about the latest science behind the use of cutting edge
CAIM protocols and bioidentical hormones in the practice of
integrative medicine. ACAM’s President, Dr Allan Magaziner
commented, ‘We had a record number of new attendees at this
convention and their level of satisfaction and desire to attend
future meetings was astounding. I encourage any forward-
thinking physician or health care practitioner to attend the
November 2005 ACAM meeting in Anaheim since it, too,
promises to offer the highest level of practical applications
and education in alternative, complementary and integrative
medicine’.
A complete list of conference presentations can be found
following this article.
In addition to the many exciting presentations at the scient-
ific conference, ACAM offered in-depth 2 day preconference
workshops on Mesotherapy and on Heavy Metal Toxicity
along with a 1 day workshop on Scientific Writing.
Edwin Cooper, PhD, Distinguished Professor, Department
of Neuroimmunology, at the David Geffen School of Medicine
For reprints and all correspondence: Stephen A. Feig, D.O. c/o The American
College for Advancement in Medicine, 23121 Verdugo Drive, Suite 204,
Laguna Hills, CA 92653, USA. Tel: þ949-583-7666; Fax: þ949-455-9679;
E-mail: info@acam.org
 The Author (2005). Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety
but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.orgat University of California, Los Angeles, chaired ACAM’s
first Writer’s Workshop held for those interested in developing
their scientific writing skills. It was well attended and quite
helpful in developing a foundational perspective on the art
and science of writing for the peer reviewed scientific literat-
ure. Several participants brought their work for review and
received constructive advice on optimizing their presentations
for submission to medical journals. ACAM will be repeating
this important workshop preceding the November 2005 meet-
ing in Anaheim, CA, USA.
ACAM’s president Dr Allan Magaziner chaired ACAM’s
popular workshop on ‘Introducing Aesthetic Mesotherapy
Into Your Practice’. Mesotherapy was originally developed
in France by Dr Michel Pistor and is currently being admin-
istered by more that 15000 doctors in France. Mesotherapy
involves the injection of vitamins, minerals, amino acids,
homeopathics and other biologicals, and can help with body
sculpting, weight loss, cellulite reduction, wrinkle reduction
and facial rejuvenation.
Peter A. Salas, MD, a Board Certified Plastic Surgeon,
presented data from his studies, which supported the use of
mesotherapy as a valuable and effective treatment in aesthetic
medicine. In research presented at meetings of the American
Society for Aesthetic Plastic Surgery and the American
Society of Plastic Surgeons (ASPS), Dr Salas demonstrated
reduction in abdominal fat as measured by improvement in
abdominal circumference and pinch test compared with
placebo. There was a high degree of patient satisfaction. He
also noted that a combination of therapeutic agents was
superior to a single agent. Additionally, in patients who under-
went treatment of lower eyelid fat pads, 90% of patients
reported improvement. Dr Salas is conducting additional
studies to be presented at a future ASPS meeting. ACAM
is the first medical organization to teach a combination of
classical mesotherapy, biomesotherapy and lipodissolve at
one conference.
In the ‘Heavy Metal Toxicity Workshop’, groundbreaking
progress was made in developing a consensus among leading
physicians and scientific experts regarding provocative urine
challenge testing protocols using multiple chelating agents
for maximal diagnostic reliability. The Workshop Chairman,
Ralph Miranda, MD, stated, ‘We made a definite leap in our
understanding of the breadth of toxic effects attributable to
metals in the wrong tissue at the wrong levels at the wrong
time, as well as the wide array of therapeutic options we can
use to accelerate removal and mitigate toxic effects of metals’.
The ‘Heavy Metal Toxicity Workshop’ educated participants
about the emerging biochemical and pathologic ‘smoking
guns’ causally linking Alzheimer’s type dementia, autistic
spectrum disorders, autoimmune disorders and other clinical
challenges with the detrimental effects of toxic metals. The
exchanges among participants and faculty were stimulating
and resulted in great progress in the understanding of laborat-
ory diagnostics and the treatment of metal toxicity.
On the final day of the conference, ACAM’s Conference
Co-Chair Eleanor Hynote, MD, presented Alexander Schauss,
PhD, with the 2005 Linus Pauling Lecture Award in
recognition of his outstanding contributions to the medical
sciences. Dr Schauss is the Director of Natural and Medicinal
Products Research for the American Institute for Biosocial
and Medical Research. The award is in honor of Dr Linus
Pauling, the only person in the world to have won two
unshared Nobel Prizes, in 1954 for Chemistry and in 1962
for Peace. ‘Linus Pauling inspired me to go into research on
nutrients and nutraceutical ingredients back in the 1970s, and
I greatly respect and admire his work’, stated Schauss.
For 25 years, Schauss has been the lead scientist for the
American Institute for Biosocial and Medical Research, Inc.,
in Tacoma, WA, USA. He is also the author or co-author of
more than 100 scientific papers in a diverse range of journals,
and recently completed his 12th book, on the subject of intra-
abdominal obesity in males. A former professor of natural
products research and associate professor of research at two
academic institutions, he is currently adjunct research pro-
fessor of botanical medicine at the National College of
Naturopathic Medicine in Portland, Oregon. Dr Schauss
has served on several National Institute of Health advisory
councils, been a reviewer of botanical monographs for the US
Pharmacopeia Convention and the International Bibliographic
Information on Dietary Supplements database (maintained
through an interagency partnership with the Food and Nutri-
tion Information Center), National Agricultural Library, NIH
Office of Dietary Supplements and the US Department of
Agriculture.
Anyone who missed the opportunity to attend ACAM’s
scientific conference ‘Menopause, Andropause: Power in
Transition’ or the preconference workshops on ‘Scientific
Writing, Introducing Aesthetic Mesotherapy Into Your
Practice’ and/or the ‘Heavy Metal Toxicity Workshop’ can
order tapes/CD’s from http://www.acam.org or through tele-
phone (þ1-800-532-3688 or 949-583-7666).
The American College for Advancement in Medicine
(ACAM) is a not-for-profit professional medical organization
for physicians interested in learning about evidence-based
CAIM therapies. ACAM’s goals are to improve skills, know-
ledge and diagnostic procedures as they relate to complement-
ary and alternative medicine; to support research; and to
develop awareness of alternative methods of medical treat-
ment. ACAM is dedicated to educating physicians and other
health care professionals on the latest findings and emerging
procedures in CAIM, botanical medicine, environmental
medicine and in the use of effective evidence-based nutritional
therapeutics. As the voice of CAIM, ACAM strives to increase
awareness and recognition of complementary, alternative and
integrative medical therapies, and play an active role in
shaping the future of the CAIM movement.
ACAM represents nearly 1000 physicians in 30 countries and
is the largest and oldest organization of its kind in the world
dedicated to providing its members with educational excellence
in integrative medicine. ACAM’s leading edge educational
programming facilitates the incorporation of clinically relevant
biomedical therapies by fast-tracking scientific advancements
414 Meeting Reportin nutritional medicine, nutraceuticals and ethnopharmacology
into the practice of cutting edge CAIM medicine.
ACAM was the first major medical organization to educate
its members about such now well-accepted concepts as insulin
resistance/metabolic syndrome, the detrimental effects of
homocysteine, the protective effects of antioxidants, the clin-
ical uses of essential fatty acids, cancer chemoprotection ther-
apies with diet and herbs, testing for cardiosensitive C-reactive
protein, the benefits of natural thyroid replacement and
nutritional medicine as applied to psychiatry.
ACAM’s next scientific conference ‘Scientific Integrative
Medicine: Advancing Health Horizons’ will be held at the
Anaheim Hilton from November 9–13, 2005. Workshop topics
include a 2-day ‘Nutrition Review and Certification’ course in
collaboration with the American College of Nutrition
(approved for 16 CMEs), ‘Prolotherapy’, a 2-day course in
partnership with the University of Wisconsin, Medical School
(approved for 15 CMEs), ‘Managing Heavy Metal Toxicity
and Mitigating Disease’ an updated 2-day course for physi-
cian, nurses and technicians, ‘Hyperbaric Oxygen Therapy’,
a 2-day course in collaboration with the International Hyper-
baric Association (approved for 15 CMEs), and ACAM’s
Scientific Writing Workshop (approved for 7.5 CMEs). For
further information, please call ACAM at þ1-800-532-3688
(in the USA) or þ1-949-583-7666 (outside the USA) or
register online at http://www.acam.org.
Summary of Presentations
Thierry Hertoghe, MD
Dr Hertoghe is the President of the World Society of
Anti-aging Medicine and the European Academy of Quality
of Life and Longevity Medicine. As the Co-Founder of the
International Hormone Society and a third generation
endocrinologist, he lectures all over the world on effective
endocrine management in the aging patient.
Treatment of Partial Growth Hormone, Testosterone
and Cortisol Deficiencies in Adults
Dr Hertoghe’s review focused heavily on the clinical correla-
tions between growth hormone (GH), testosterone, and cortisol
deficiencies. Moreover, it highlighted the changes in physical
appearance before and after GH replacement therapy and cat-
egorized two clinical syndromes of GH deficiency, which
include clear improvement in lean body mass and resolution
of anxiety and depression after initiation of therapy. He
detailed the following benefits of GH replacement therapy:
(i) reduction in total serum cholesterol, low-density lipoprotein
and the cholesterol/high-density lipoprotein ratio after treat-
ment with GH; (ii) decreased incidence of Crohn’s disease;
(iii) improvement in bone mineral density after 1 year of
replacement therapy; (iv) better sleep; and (v) reduction in
overall mortality rates and Myocardial Infarctions (MI) in
hypopituitary patients who received growth hormone replace-
ment therapy (GHRT).
Dr Hertoghe reviewed androgen and age-related diseases,
detailing the Male Climacteric Syndrome and the benefit of
androgen replacement therapy in this setting. He reviewed
older literature, which showed that administration of
dihydrotestosterone gel actually induced a 15% reduction in
the size of the prostate. He detailed the connection between
elevated estrogen levels in men and increase in prostate
stroma. Dr Hertoghe took a similar approach in describing
the clinical effects of cortisol with age-related diseases. He
closed his lecture by reviewing the laboratory evaluation of
androgen and cortisol deficiency, and the hormonal interven-
tion needed to correct the described abnormalities.
Michael Galitzer, MD
Dr Galitzer is a board certified emergency medicine physician
who practices integrative medicine in California, USA.
The Bioenergetic Evaluation and Treatment of
Menopause
Dr Galitzer reviewed the various facets of menopause, noting
that for proper hormonal functioning one must view the endo-
crine system as an integrated whole. He maintained that meno-
pause was not only an issue of estrogen and progesterone (P4)
deficiency but also related to adrenal, thyroid, pancreatic hor-
mones, as well as testosterone. Additionally, he reviewed the
concepts of metabolic typing and liver detoxification and the
role they play in menopause and the general management of
the ill patient. Objective evaluation of the hormonal axis and
autonomic nervous system is achieved through the use of heart
rate variability, a good history that includes assessment of
environmental and emotional stressors to the adrenal gland,
and proper use of the laboratory, including salivary, urine
or blood hormone levels and biological terrain assessment.
Therapeutic interventions were reviewed, including exercise,
supplements, relaxation techniques, acupuncture and homeo-
pathic interventions. Dr Galitzer’s presentation was an excel-
lent overview of the integrative approach to menopause and
the factors leading to a chronically stressed endocrine system.
Allan Warshowsky, MD, FACOG
Dr Warshowsky is a board certified OBGYN who serves as an
attending staff physician at New York’s Beth Israel Medical
Center and is the author of ‘Healing Fibroids: A Doctors Guide
to a Natural Cure’.
Holistic Healing of Fibroid Tumors of the Uterus
Dr Warshowsky reviewed an integrative approach to the
assessment and treatment of fibroid tumors. He presented
data showing that patients who received an integrative
approach had a mean decrease in fibroid tumor size of 0.8 cm
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1.9 cm. Dr Warshowsky emphasized the importance of proper
diet, hormone balancing, good gastrointestinal and liver
support, and the use of P4 and melatonin. Additionally,
he detailed the use of herbal and homeopathic interventions,
including Scudders Alterative, Echinacea, Fraxinus Cean-
othus, Aconite, Phytolacca, Gelsemium, Vitex (chasteberry),
Aurum Muriaticaum and Hydrastinum Muriaticum in the man-
agement of patients with fibroid tumors.
Jeanette Graf, MD, FAAD
Dr Graf is a board certified dermatologist in private practice.
She previously served as an NIH research fellow in the area
of extracellular matrix components.
The Care of Aging Skin—from Cosmeceutical to
Cosmolecular
Dr Graf’s presentation reviewed the transition of skin care
products from cosmeceuticals to cosmoleculars and she made
the point that skin rejuvenation would ultimately be achieved
at the molecular level via altering signal transduction. Dr Graf
reviewed the factors involved in skin aging, which typically
originate with oxidative stress related to cigarette smoke,
genetics, other environmental stressors, UVA and UVB.
Potential targets for skin rejuvenation therapies included
collagen, collagen-degrading enzymes known as matrix metal-
loproteinases (MMPs) and skin membrane lipids. Relevant
nutrients, which were discussed as potential agents for slowing
the aging process of skin include: (i) topical vitamin A, which
appears to regulate gene transcription and inhibit MMPs and
has been documented to increase collagen bundles resulting
in dermal thickening, improved skin tone and reduced signs
of photoaging; (ii) tocopherols, which are fat-soluble and
known to neutralize free radicals in the cell membrane;
(iii) vitamin C, which functions as a tyrosinase inhibitor, a
cofactor in hydroxylation of collagen and an inhibitor of
MMP-1; (iv) idebenone, an analog of CoQ10; (v) alpha and
beta hydroxy acids, which are used as exfoliants; (vi) tissue
respiratory factors from yeast that promote cellular respiration
and cell renewal; (vii) beta glucans; (viii) zinc, which func-
tions as a cofactor for the antioxidant enzyme superoxide dis-
mutase; (ix) copper, which serves as a promoter of collagen
formation; and (x) polyphenols, which include flavonoids
from soy, green tea catechins, carotenoids and procyanidins.
Dr Graf concluded her presentation by making the essential
point that synergy among nutrients was paramount for long-
term skin management.
T.S. Wiley
T.S. Wiley is an anthropologist and the author of ‘Sex, Lies,
and Menopause’. She is a member of the New York Academy
of Sciences and has been a guest investigator at Sansum
Medical Research Institute.
MultiPhasic, Cyclical Hormone Therapy with
Bioidentical E2/P4
Postulating that the cyclic hormone pattern and serum levels of
perimenopausal and post-menopausal women should mimic
that of women in their 20s, T.S. Wiley has generated a protocol
with the use of transdermal bioidentical estradiol (E2) and
P4 that is multiphasic and cyclic. Ms Wiley’s presentation
described the rational and early clinical experiences in using
high-dose bioidentical hormone replacement therapy. The
initial results of this therapy protocol have been positive and
plans are underway to expand her clinical trial for statistical
validation.
During the question and answer period, some concerns were
raised about the protocol. These includes (i) whether or not
serum levels were an acceptable marker for hormones that
were administered transdermally; (ii) that some women had
experienced significant side effects while following the proto-
col and had stopped using it; and (iii) the dosage of hormones
used was too high and not physiologic.
Lindsey Berkson, MA, DC
Dr Berkson is presently a consulting scholar at the Center
for Bioenvironmental Research at Tulane and Xavier Univer-
sities as well as the author of seven books on health and the
environment.
Endocrine Disruption Update and Relevance in
Clinical Practice
Dr Berkson reviewed the clinical relevance of endocrine
disrupting chemicals. She discussed signal transduction and
the impact of hormones and hormone mimics on gene
transcription and suppression; specifically citing the similarit-
ies of di-ethyl-stilboestrol (DES), Dichlorodiphenyltrichlor-
oethane (DDT) and bisphenol-A to E2. Dr Berkson’s
presentation reviewed the interplay, interdependence and
downstream influence of various hormones upon one another
and elegantly classified compounds known to be endocrine
disruptors, which include: Polychlorinated biphenyls
(PCBs), DDT, dioxins, pyrethroids, cadmium, lead, methoxy-
chlor, etc.
The presentation briefly explained the mechanisms of action
of many endocrine disrupters, which include competitive
binding to the hormone binding globulins, interference with
metabolic pathways of endogenous hormones, competitive
binding to nuclear receptors, inhibition of the dimerization
of the ligand–nuclear receptor complex, interference with the
coupling between the dimer complex and the DNA response
elements and the down-regulation of receptors.
Eugene Shippen, MD
Dr Shippen is the author of the best selling book, ‘The
Testosterone Syndrome’.
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Dr Shippen’s lecture focused on the important role of testoster-
one in the aging process. He highlighted the many changes that
occur with aging including the shift from Th2 to Th1 response
and the resulting movement toward a more proinflammatory
state. He emphasized that treatments with androgens, P4 and
vitamin D tend to shift T lymphocytes from Th1 dominance
back toward Th2 dominance thereby implying less inflamma-
tion. However, E2 results in excess shifts toward a more
proinflammatory state. Additionally, he covered the potential
role of MMP activity in the degradation and rupture of the
fibrous cap of many vascular plaques. Interestingly, it appears
that the activity of MMP is down-regulated in the presence of
normal levels of testosterone and up-regulated in the presence
of E2.
Dr Shippen made the point that many chronic diseases are
associated with low testosterone and that treating these ill-
nesses with androgen replacement therapy may offer relief.
He also reviewed many classes of drugs that may lower testo-
sterone, including antifungals, anticonvulsants, glucocortic-
oids, phenothiazines, calcium channel blockers, diuretics,
statins and others.
Joel Evans, MD
Dr Evans is an assistant professor of both the Albert Einstein
College of Medicine and the College of Physicians and
Surgeons at Columbia University. He is also the Founder and
Director of the Center for Women’s Health in Darien,
CT, USA.
The Use of Genomic Testing to Assess Risks and
Benefits of Hormone Replacement Therapy
Many physicians are facing difficult decisions regarding
initiating HRT. An individualized approach can include the
use of predictive genomic testing. A considerable amount of
research has been done to assess the effect of HRT on those
who carry specific single nucleotide polymorphisms (SNPs).
In many cases, the presence of a particular SNP can signific-
antly increase or decrease a women’s risk of complications
from HRT. Certain SNPs can affect coagulation, such that
women who are on HRT with the G!A polymorphism at
position 20210A on chromosome 11 will have a higher risk
for thromboembolic events. Genomic testing can also help to
assess breast cancer risk in patients treated with HRT.
CYP1A1 produces 2-OH estrogens and decreased activity
of this cytochrome leads to increased breast cancer
risk. Similarly, CYP1B1 produces 4-OH estrogens so that
increased activity leads to increased ovarian and breast
cancer risk.
Eric Serrano, MD
Dr Serrano is a Professor at Ohio State University.
Hormones: What are they and What They Do
Dr Serrano reviewed the general effects on hormone metabol-
ism in relationship to obesity and explained how hormones,
produced by the hypothalamus and the pituitary gland, are
secreted in a burst-like fashion. Additionally, he reviewed the
circadian rhythm of hormones such as GH and adrenocortico-
trophin hormone (ACTH) and noted that these hormones have
increased secretion during specific hours of the day. Circadian
rhythms of hormone secretion have a direct influence on
metabolism such that the first meal of the day has the
ability to alter ones metabolic rate and ones ability to burn cal-
ories efficiently for the remainder of the day. Also, sex hor-
mones influence metabolism such that the optimal time to
exercise and burn the most calories is during the follicular
phase of the menstrual cycle. Dr Serrano also noted that
many obese patients have a higher accumulation of biotoxins
and subsequently a 30% lower ability to burn calories
efficiently.
Debu Tripathy, MD
Dr Tripathy is Professor of Internal Medicine and Director of
Komen, University of Texas Southwestern Breast Cancer
Research Program at the University of Southwestern Medical
Center in Dallas, TX, USA.
Models of Research for Complementary Medicine in
Breast Cancer
Models of Integrative Cancer Research have included surveys
(population-based, center-based and recruited), observational
cohort studies and case-control studies. There are far fewer
prospective and placebo-controlled trials. Dr Tripathy dis-
cussed his work in designing a ‘Pilot Phase I Study of Tibetan
Herbal Therapy for Advanced Breast Cancer’. Individuation
rather than single agent therapy is necessary and the basis of
choosing herbal formulae is not defined by standard clinical
or scientific criteria. Dr Tripathy’s study was designed to pre-
serve the individualization of care by using the expertise of a
Tibetan physician who determined treatment formulae based
on history and physical examination. Eleven patients with
minimally symptomatic measurable advanced breast cancer
were treated with a Tibetan herbal formula as their only treat-
ment. Assessments of tumor progression were performed and
patients were treated until tumor progressed. The results
revealed that none of the patients had significant toxicities.
One of the nine patients had a significant partial response
after 4 months. One patient had stable disease for greater
than 1 year.
Mark Blumenthal
Mark Blumenthal is the Founder and Executive Director of
the American Botanical Council; an independent, non-profit
organization dedicated to disseminating accurate, reliable and
responsible information on herbs and medicinal plants. He
is the Editor/Publisher of HerbalGram, an international,
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Adjunct Associate Professor of Medicinal Chemistry at the
College of Pharmacy, University of Texas at Austin. Mark
has served as Co-Founder and former Vice President of the
Herb Research Foundation and President of the Herb Trade
Association. He was also a founding board member of the
American Herbal Products Association. He is the senior editor
of the English translation of The Complete German Commis-
sion E Monographs—Therapeutic Guide to Herbal Medicines,
a rational system for evaluating the safety and efficacy of
herbal medicines. Mark is the senior editor of The American
Botanical Council’s Clinical Guide to Herbs, a new reference
work and continuing education module.
Review of the Research on Botanical Medicines for
Treating the Symptoms of Menopause and ‘Manopause’
Mr Blumenthal reviewed the clinical evidence and the safety
data for the use of black cohosh, red clover extract and soy iso-
flavones in the treatment of menopausal symptoms. Studies
documenting the safety and efficacy of saw palmetto, pygeum
bark and nettle root were discussed in relationship to assisting
men with the symptoms of andropause.
Dennis Villareal, MD
Dr Villareal is Assistant Professor of Medicine in Geriatrics
and Nutritional Science and Director of Geriatric Consultation
Service at the Barnes-Jewish Hospital at Washington
University.
DHEA and the Metabolic Syndrome
Dr Villareal made the following points in regards to his ori-
ginal research on Dehydroepiandrosterone (DHEA): (i) the
adrenal production of DHEA declines dramatically with aging
in humans. Low DHEA levels have been correlated with
abdominal obesity, glucose intolerance, insulin resistance and
atherosclerosis; (ii) higher DHEA levels have been correlated
with longer survival; and (iii) DHEA is the most abundant
hormone in the human body.
His research addressed the question of whether DHEA
replacement is beneficial. Dr Villareal presented his data
showing that there is a measurable decrease in visceral fat
with DHEA replacement in elderly women and men. This
decrease in adipose tissue will result improved insulin
resistance. Although there was no impact of DHEA supple-
mentation on testosterone levels in men, women who were
supplemented with DHEA showed an increase of testosterone,
which mimicked levels that are more youthful. Dr Villareal’s
research also revealed a slight increase in insulin-like growth
factor-1 (IGF-1) in both women and men supplemented with
DHEA. There were no serious adverse effects related to
DHEA replacement. No changes in liver and renal chemistries
were observed and, in fact, there was a slight downward trend
in PSA levels in men.
Alexander Schauss, PhD
Dr Schauss is the author of ‘Minerals, Trace Elements and
Human Health’ and serves as the Director of Natural and
Medicinal Products Research at AIBMR Life Sciences, Inc.
Minerals: Achieving the Proper Balance
Recent research indicates that supplemental minerals and trace
elements may play a significant role in maintaining health and
preventing disease. Nevertheless, they must exist in balance
and ingestion of these nutrients does not come without risk in
some cases when there is a lack of safety data and toxicology.
Dr Schauss discussed the potential harmful effect of chronic
germanium ingestion and potential toxicity of vanadium
supplementation. Of particular concern is the accumulation
of vanadium into the kidneys and other tissues. Dr Schauss
pointed out that safer forms of vanadium supplements, such
as vanadyl–methylpicolinate complex, are now available. He
also discussed the importance of selenium as a trace mineral
and indicated that depletion of selenium is known to cause
disease, especially with impairment of the immune system.
Selenomethionine was discussed as the best source for human
ingestion.
Cynthia Browne, MD, PhD
Dr Brown is Director of Complementary Cancer Care at the
Van Elslander Cancer Center located in Gross Point Woods,
MI, USA.
Estrogen Metabolic Pathways: the Road to
Health or Disease
Dr Brown’s presentation examined how various toxins, exo-
toxins, hormones and drugs are processed by the liver in a
two-step process of Phase I and Phase II detoxification. She
described the various forms of estrogen (E1, E2 and E3) and
the complex interaction with other hormones on their path to
metabolism and excretion. Variations in p450 enzymes in
Phase I detoxification can affect the ratio of E2 and estrone
2-OH, 16 alpha-hydroxy and 4-hydroxy metabolites. These
have implications for health and disease as further metabolites
through Phase II conjugation have varying properties of bio-
chemical significance. Dr Brown explained that the ultimate
effect of estrogen depends on how it is metabolized, and that
genetics and nutrients dictate estrogen metabolism through
methylation, glucuronidation and sulfation. The contribution
of cancer risk is from total estrogen load as well as types of
metabolites. Estrogen metabolism is also influenced by aro-
matase activity. Higher aromatase levels increase estrogen
load and some of the factors that increase aromatase include
obesity and inflammation. Dr Brown explained how nutri-
tional interventions influence estrogen metabolism and physi-
ology. Although the efficacy of indole-3 carbinol depends on
stomach pH to convert to Diindolemethane (DIM), both nutri-
ents have similar beneficial effects of improving 2-OH estrone
to 16 alpha-OH estrone ratios. It appears that not all beneficial
418 Meeting Reporteffects are from DIM as other metabolites from 13C, such as
indolylcarbazole, can induce CYP1A1 and CYP13C but have
a greater effect on CYP3A4 than DIM in vivo.
John Kells, MD
Dr Kells is CEO of Aeron Labs.
Salivary Bioavailable Testosterone (SBA-T) As
Compared To Serum Bioavailable (BT), Total
Testosterone (TT) and Calculated Free Testosterone
Index (cFT)
Dr Kells performed a study at St Louis University, which
compared SBA-T with BT and TT levels in 127 men aged
23–80 years. He found that SBA-T was highly significantly
correlated with BT (P < 0.001). Dr Kells noted that testoster-
one appeared to be a biomarker for longevity in women but its
significance as a predictor of longevity in men was uncertain.
The conclusion of Dr Kells study was that his data support
the legitimacy of using SBA-T to measure bioeffective, tissue
available testosterone and that SBA-T was clinically useful in
the diagnosis of hypogonadism.
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